journal
Journals Neurotherapeutics : the Journa...

Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics

https://read.qxmd.com/read/38580511/mitochondrial-transplantation-exhibits-neuroprotective-effects-and-improves-behavioral-deficits-in-an-animal-model-of-parkinson-s-disease
#21
JOURNAL ARTICLE
Hyeyoon Eo, Shin-Hye Yu, Yujin Choi, Yujin Kim, Young Cheol Kang, Hanbyeol Lee, Jin Hee Kim, Kyuboem Han, Hong Kyu Lee, Mi-Yoon Chang, Myung Sook Oh, Chun-Hyung Kim
Mitochondria are essential organelles for cell survival that manage the cellular energy supply by producing ATP. Mitochondrial dysfunction is associated with various human diseases, including metabolic syndromes, aging, and neurodegenerative diseases. Among the diseases related to mitochondrial dysfunction, Parkinson's disease (PD) is the second most common neurodegenerative disease and is characterized by dopaminergic neuronal loss and neuroinflammation. Recently, it was reported that mitochondrial transfer between cells occurred naturally and that exogenous mitochondrial transplantation was beneficial for treating mitochondrial dysfunction...
April 4, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/38580510/high-definition-transcranial-direct-current-stimulation-desynchronizes-refractory-status-epilepticus
#22
JOURNAL ARTICLE
Darion B Toutant, Hussam El-Alawi, Eun Hyung Choi, Natalie Wright, Manzuma Khanam, Bojan Paunovic, Ji Hyun Ko, Marcus C Ng
Recently, we showed that high-definition transcranial direct current stimulation (hd-tDCS) can acutely reduce epileptic spike rates during and after stimulation in refractory status epilepticus (RSE), with a greater likelihood of patient discharge from the intensive care unit compared to historical controls. We investigate whether electroencephalographic (EEG) desynchronization during hd-tDCS can help account for observed anti-epileptic effects. Defining desynchronization as greater power in higher frequencies such as above 30 ​Hz ("gamma") and lesser power in frequency bands lower than 30 ​Hz, we analyzed 27 EEG sessions from 10 RSE patients who had received 20-minute session(s) of 2-milliamperes of transcranial direct current custom-targeted at the epileptic focus as previously determined by a clinical EEGer monitoring the EEG in real-time...
April 4, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/38579455/neuroscience-fundamentals-relevant-to-neuromodulation-neurobiology-of-deep-brain-stimulation-in-parkinson-s-disease
#23
REVIEW
Benjamin Davidson, Luka Milosevic, Laura Kondrataviciute, Lorraine V Kalia, Suneil K Kalia
Deep Brain Stimulation (DBS) has become a pivotal therapeutic approach for Parkinson's Disease (PD) and various neuropsychiatric conditions, impacting over 200,000 patients. Despite its widespread application, the intricate mechanisms behind DBS remain a subject of ongoing investigation. This article provides an overview of the current knowledge surrounding the local, circuit, and neurobiochemical effects of DBS, focusing on the subthalamic nucleus (STN) as a key target in PD management. The local effects of DBS, once thought to mimic a reversible lesion, now reveal a more nuanced interplay with myelinated axons, neurotransmitter release, and the surrounding microenvironment...
April 4, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/38579454/unraveling-the-threads-of-stability-a-review-of-the-neurophysiology-of-postural-control-in-parkinson-s-disease
#24
REVIEW
Jessica E Bath, Doris D Wang
Postural instability is a detrimental and often treatment-refractory symptom of Parkinson's disease. While many existing studies quantify the biomechanical deficits among various postural domains (static, anticipatory, and reactive) in this population, less is known regarding the neural network dysfunctions underlying these phenomena. This review will summarize current studies on the cortical and subcortical neural activities during postural responses in healthy subjects and those with Parkinson's disease...
April 4, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/38575503/regulating-lars2-in-mitochondria-a-potential-alzheimer-s-therapy-by-inhibiting-tau-phosphorylation
#25
JOURNAL ARTICLE
Wenqi Qian, Lin Yuan, Weishan Zhuge, Liuqing Gu, Yutian Chen, Qichuan Zhuge, Haoqi Ni, Xinhuang Lv
Driven by the scarcity of effective treatment options in clinical settings, the present study aimed to identify a new potential target for Alzheimer's disease (AD) treatment. We focused on Lars2, an enzyme synthesizing mitochondrial leucyl-tRNA, and its role in maintaining mitochondrial function. Bioinformatics analysis of human brain transcriptome data revealed downregulation of Lars2 in AD patients compared to healthy controls. During in vitro experiments, the knockdown of Lars2 in mouse neuroblastoma cells (neuro-2a cells) and primary cortical neurons led to morphological changes and decreased density in mouse hippocampal neurons...
April 3, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/38570276/berberine-inhibits-nlrp3-inflammasome-activation-and-proinflammatory-macrophage-m1-polarization-to-accelerate-peripheral-nerve-regeneration
#26
JOURNAL ARTICLE
Jun Sun, Qiuhua Zeng, Zhimin Wu, Lixin Huang, Tao Sun, Cong Ling, Baoyu Zhang, Chuan Chen, Hui Wang
Berberine (BBR) has demonstrated potent anti-inflammatory effects by modulating macrophage polarization. Nevertheless, the precise mechanisms through which berberine regulates post-injury inflammation within the peripheral nerve system remain elusive. This study seeks to elucidate the role of BBR and its underlying mechanisms in inflammation following peripheral nerve injury (PNI). Adult male C57BL/6J mice subjected to PNI were administered daily doses of berberine (0, 60, 120, 180, 240 ​mg/kg) via gavage from day 1 through day 28...
April 2, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/38531713/extended-interval-dosing-of-natalizumab-more-evidence-in-support
#27
JOURNAL ARTICLE
Karlo Toljan, Devon S Conway
No abstract text is available yet for this article.
March 25, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/38521667/pharmacodynamic-rationale-for-the-choice-of-antiseizure-medications-in-the-paediatric-population
#28
REVIEW
Gianluca D'Onofrio, Roberta Roberti, Antonella Riva, Emilio Russo, Alberto Verrotti, Pasquale Striano, Vincenzo Belcastro
In the landscape of paediatric epilepsy treatment, over 20 anti-seizure medications (ASMs) have gained approval from Drug Regulatory Agencies, each delineating clear indications. However, the complexity of managing drug-resistant epilepsy often necessitates the concurrent use of multiple medications. This therapeutic challenge highlights a notable gap: the absence of standardized guidelines, compelling clinicians to rely on empirical clinical experience when selecting combination therapies. This comprehensive review aims to explore current evidence elucidating the preferential utilization of specific ASMs or their combinations, with a primary emphasis on pharmacodynamic considerations...
March 22, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/38493058/neuroprotective-effects-of-niclosamide-on-disease-progression-via-inflammatory-pathways-modulation-in-sod1-g93a-and-fus-associated-amyotrophic-lateral-sclerosis-models
#29
JOURNAL ARTICLE
Martina Milani, Ilaria Della Valle, Simona Rossi, Paola Fabbrizio, Cassandra Margotta, Giovanni Nardo, Mauro Cozzolino, Nadia D'Ambrosi, Savina Apolloni
Amyotrophic lateral sclerosis (ALS) is a complex neurodegenerative disease influenced by genetic, epigenetic, and environmental factors, resulting in dysfunction in cellular and molecular pathways. The limited efficacy of current treatments highlights the need for combination therapies targeting multiple aspects of the disease. Niclosamide, an anthelminthic drug listed as an essential medicine, has been repurposed in clinical trials for different diseases due to its anti-inflammatory and anti-fibrotic properties...
March 15, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/38493057/application-of-targeted-liposomes-based-salvianolic-acid-a-for-the-treatment-of-ischemic-stroke
#30
JOURNAL ARTICLE
Ming-Yan Yang, Yu Liu, Ya-Wen Yu, Bai-Fang Gong, Jian Ruan, Hua-Ying Fan
Novel therapeutics for the treatment of ischemic stroke remains to be the unmet clinical needs. Previous studies have indicated that salvianolic acid A (SAA) is a promising candidate for the treatment of the brain diseases. However, SAA has poor absolute bioavailability and does not efficiently cross the intact blood-brain barrier (BBB), which limit its efficacy. To this end we developed a brain-targeted liposomes for transporting SAA via the BBB by incorporating the liposomes to a transport receptor, insulin-like growth factor-1 receptor (IGF1R)...
March 15, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/38490875/effectiveness-analysis-of-three-drug-combination-therapies-for-refractory-focal-epilepsy
#31
JOURNAL ARTICLE
Chunmei Wu, Huiting Wu, Yingying Zhou, Xiaoyan Liu, Shanshan Huang, Suiqiang Zhu
Selecting appropriate antiseizure medications (ASMs) for combination therapy in patients with drug-resistant epilepsy (DRE) is a complex task that requires an empirical approach, especially in patients receiving polytherapy. We aimed to analyze the effectiveness of various three-drug combinations in a group of patients with DRE under real-world conditions. This single-center, longitudinal observational study investigated patients with drug-resistant focal epilepsy who received three-drug regimens in the outpatient clinic of Tongji Hospital from September 2019 to December 2022...
March 14, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/38472048/vegf-expression-disparities-in-brainstem-motor-neurons-of-the-sod1-g93a-als-model-correlations-with-neuronal-vulnerability
#32
JOURNAL ARTICLE
Silvia Silva-Hucha, M Estrella Fernández de Sevilla, Kirsty M Humphreys, Fiona E Benson, Jaime M Franco, David Pozo, Angel M Pastor, Sara Morcuende
Amyotrophic lateral sclerosis (ALS) is a rare neuromuscular disease characterized by severe muscle weakness mainly due to degeneration and death of motor neurons. A peculiarity of the neurodegenerative processes is the variable susceptibility among distinct neuronal populations, exemplified by the contrasting resilience of motor neurons innervating the ocular motor system and the more vulnerable facial and hypoglossal motor neurons. The crucial role of vascular endothelial growth factor (VEGF) as a neuroprotective factor in the nervous system is well-established since a deficit of VEGF has been related to motoneuronal degeneration...
March 11, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/38453562/neuroprotective-efficacy-of-hypothermia-and-inter-alpha-inhibitor-proteins-after-hypoxic-ischemic-brain-injury-in-neonatal-rats
#33
JOURNAL ARTICLE
Xiaodi F Chen, Yuqi Wu, Boram Kim, Kevin V Nguyen, Ainuo Chen, Joseph Qiu, Andre R Santoso, Clemence Disdier, Yow-Pin Lim, Barbara S Stonestreet
Therapeutic hypothermia is the standard of care for hypoxic-ischemic (HI) encephalopathy. Inter-alpha Inhibitor Proteins (IAIPs) attenuate brain injury after HI in neonatal rats. Human (h) IAIPs (60 ​mg/kg) or placebo (PL) were given 15 ​min, 24 and 48 ​h to postnatal (P) day-7 rats after carotid ligation and 8% oxygen for 90 ​min with (30 ​°C) and without (36 ​°C) exposure to hypothermia 1.5 ​h after HI for 3 ​h...
March 6, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/38734464/neuromodulation-update-on-current-practice-and-future-developments
#34
EDITORIAL
Vibhor Krishna, Alfonso Fasano
No abstract text is available yet for this article.
April 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/38688105/neurosurgical-neuromodulation-therapy-for-psychiatric-disorders
#35
REVIEW
Manish Ranjan, James J Mahoney, Ali R Rezai
Psychiatric disorders are among the leading contributors to global disease burden and disability. A significant portion of patients with psychiatric disorders remain treatment-refractory to best available therapy. With insights from the neurocircuitry of psychiatric disorders and extensive experience of neuromodulation with deep brain stimulation (DBS) in movement disorders, DBS is increasingly being considered to modulate the neural network in psychiatric disorders. Currently, obsessive-compulsive disorder (OCD) is the only U...
April 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/38430811/neuromodulation-for-the-treatment-of-prader-willi-syndrome-a-systematic-review
#36
REVIEW
Liming Qiu, Andrew Chang, Ruoyu Ma, Theresa V Strong, Michael S Okun, Kelly D Foote, Anna Wexler, Aysegul Gunduz, Jennifer L Miller, Casey H Halpern
Prader-Willi syndrome (PWS) is a complex, genetic disorder characterized by multisystem involvement, including hyperphagia, maladaptive behaviors and endocrinological derangements. Recent developments in advanced neuroimaging have led to a growing understanding of PWS as a neural circuit disorder, as well as subsequent interests in the application of neuromodulatory therapies. Various non-invasive and invasive device-based neuromodulation methods, including vagus nerve stimulation (VNS), transcranial direct current stimulation (tDCS), repetitive transcranial magnetic stimulation (rTMS), and deep brain stimulation (DBS) have all been reported to be potentially promising treatments for addressing the major symptoms of PWS...
March 1, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/38413275/treatment-modifiers-across-different-regimens-of-natalizumab-treatment-in-ms-an-italian-real-world-experience
#37
JOURNAL ARTICLE
Serena Ruggieri, Antonio Ianniello, Massimiliano Copetti, Marta Altieri, Diego Centonze, Antonio Cortese, Laura De Giglio, Roberta Fantozzi, Carla Tortorella, Claudio Gasperini, Luigi Me Grimaldi, Doriana Landi, Girolama A Marfia, Massimiliano Mirabella, Riccardo Nistri, Viviana Nociti, Oscar Oddo, Silvia Romano, Giuseppe Salemi, Marco Salvetti, Carlo Pozzilli, Maria Petracca
Despite its widespread use in clinical practice, the effectiveness of natalizumab extended interval dosing (EID) adopted from treatment start across different treatment intervals and individual modifiers (body mass index - BMI) is still under-investigated. Here, seven-hundred and forty-five multiple sclerosis (MS) patients, exposed to natalizumab for 3.30 ​± ​1.34 years, were retrospectively enrolled in an observational multicenter study. After stratifying patients in EID or standard interval dosing (SID), we assessed differences in time to relapse, MRI activity and Expanded Disability Status Scale (EDSS) progression...
February 26, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/38388224/honokiol-hexafluoro-confers-reversal-of-neuropathological-markers-of-hiv-infection-in-a-murine-scid-model
#38
JOURNAL ARTICLE
Zhan Zhang, Aaron Scanlan, Rajeth Koneru, Chelsea Richardson Morrell, Monica D Reece, Emily Edwards, Sebastian Roa, Christina Gavegnano, Heather Bimonte-Nelson, Jack Arbiser, William Tyor
Cognitive impairment remains a persistent challenge in people living with HIV (PWLH) despite antiretroviral therapy (ART) due to ART's inability to eliminate brain HIV. HIV-induced cognitive dysfunction results from immune dysregulation, ongoing neuroinflammation, and the continuous virus presence, collectively contributing to cognitive deficits. Therefore, adjunctive therapies are needed to reduce cerebral HIV reservoirs, mitigate neuroinflammation, and impede cognitive dysfunction progression. Our study focused on Honokiol, known for its anti-inflammatory and neuroprotective properties, in an experimental mouse model simulating HIV-induced cognitive dysfunction...
February 21, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/38377638/the-evolution-of-neuromodulation-for-chronic-stroke-from-neuroplasticity-mechanisms-to-brain-computer-interfaces
#39
REVIEW
Brian F Saway, Charles Palmer, Christopher Hughes, Matthew Triano, Rishishankar E Suresh, Jordon Gilmore, Mark George, Steven A Kautz, Nathan C Rowland
Stroke is one of the most common and debilitating neurological conditions worldwide. Those who survive experience motor, sensory, speech, vision, and/or cognitive deficits that severely limit remaining quality of life. While rehabilitation programs can help improve patients' symptoms, recovery is often limited, and patients frequently continue to experience impairments in functional status. In this review, invasive neuromodulation techniques to augment the effects of conventional rehabilitation methods are described, including vagus nerve stimulation (VNS), deep brain stimulation (DBS) and brain-computer interfaces (BCIs)...
February 19, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/38368172/efficacy-of-therapy-by-mk-28-perk-activation-in-the-huntington-s-disease-r6-2-mouse-model
#40
JOURNAL ARTICLE
Talya Shacham, Daniel Offen, Gerardo Z Lederkremer
There is currently no disease-modifying therapy for Huntington's disease (HD). We recently described a small molecule, MK-28, which restored homeostasis in HD models by specifically activating PKR-like ER kinase (PERK). This activation boosts the unfolded protein response (UPR), thereby reducing endoplasmic reticulum (ER) stress, a central cytotoxic mechanism in HD and other neurodegenerative diseases. Here, we have tested the long-term effects of MK-28 in HD model mice. R6/2 CAG (160) mice were treated by lifetime intraperitoneal injections 3 times a week...
February 16, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
journal
journal
41497
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.